Identification of distinct disease activity trajectories in methotrexate-naïve patients with rheumatoid arthritis receiving tofacitinib over 24 months.

Distinct phenotypic subgroups identified heterogeneity in patients with RA normally analyzed as a single population. Trajectory modeling may enable separation of clinically meaningful subsets of patients with RA, and may help optimize treatment outcomes.